|Dr. Thomas R. Cannell||Pres, CEO & Director||885.06k||N/A||1962|
|Ms. Monica Forbes||CFO & Treasurer||536k||N/A||1976|
|Dr. Glen C. MacDonald||Chief Technology Officer||519.7k||N/A||1951|
|Dr. Gregory L. Verdine||Co-Founder||N/A||N/A||1959|
|Ms. Elly Ryu||Corp. Controller & Principal Accounting Officer||N/A||N/A||1981|
|Ms. Erin Clark||VP of Corp. Strategy & Investor Relations||N/A||N/A||N/A|
|Mr. Mark R. Sullivan||Gen. Counsel & Corp. Sec.||N/A||N/A||1971|
|Mr. Steve Barbera||VP of Market Access||N/A||N/A||N/A|
|Ms. Julie Hoff||VP of HR||N/A||N/A||N/A|
|Dr. David Brooks||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Sesen Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.